Anthracycline News and Research

RSS

Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.

Remote ischemic conditioning shields the heart from chemotherapy damage

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs-a class of medicines called anthracyclines-can cause serious damage to the heart.

2 Mar 2026

Interventions to treat valvular heart disease in cancer patients significantly improve survival

Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.

11 Dec 2025

Nanoflower-treated stem cells deliver healthier mitochondria to stressed cells

This study shows that vacancy-engineered MoS₂ nanoflowers drive mitochondrial biogenesis in human mesenchymal stem cells by activating SIRT1–PGC-1α signaling and reducing oxidative stress. These treated cells transfer more functional mitochondria to injured recipient cells, restoring energy metabolism and redox balance in multiple in vitro models.

9 Dec 2025

UCLA experts call for individualized heart monitoring in breast cancer survivors

As breast cancer survival rates continue to climb - 4.3 million women in the U.S. are currently living with a history of the disease and in the next 10 years that number is expected to rise by another million - heart health has become an increasingly important part of survivorship care.

4 Nov 2025

New chemotherapeutic agent shows remarkable efficacy against multiple tumor types

A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies.

30 Oct 2025

New antibody drug conjugates can transform early HER2-positive breast cancer treatment

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

18 Oct 2025

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC/EAS Focused Update to Guidelines, about how best to manage lipid levels in patients to reduce cardiovascular risk, recommends the use of new cardiovascular risk predication algorithms. The update was published today at ESC Congress 2025.

30 Aug 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

New genomic test predicts chemotherapy resistance in cancer patients

Chemotherapy seeks to destroy tumor cells and has been a standard treatment for cancer for decades.

24 Jun 2025

New DNA test predicts chemotherapy resistance in cancer patients

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a test which can successfully predict whether cancer will resist common forms of chemotherapy treatment.

23 Jun 2025

New clinical trial tests non-invasive method to protect hearts during chemotherapy

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested in a Phase II clinical trial to see if it can help cancer patients treated with common chemotherapy drugs, called anthracyclines, avoid heart failure.

20 Jun 2025

Diabetes drug could reduce heart failure in cancer survivors

A common type of diabetes medication could help cancer patients make a better long-term recovery, according to new research from the University of East Anglia.

5 Mar 2025

Scientists design strategy for preventing cardiotoxic effects of anthracyclines

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic effects of anthracyclines, a widely used class of anticancer drugs.

4 Feb 2025

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs.

23 Jan 2025

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Cardio-oncology experts highlight importance of heart health in cancer care

The devastating news of a cancer diagnosis understandably makes doctors and patients focus on the cancer itself.

13 Dec 2024

Serum protein panel test can help identify cardiomyopathy risk in childhood cancer survivors

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, effective ways to predict disease risk is a tremendous challenge.

3 Dec 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

SwRI collaborates with UTSA to develop novel chemical process for synthesizing antibiotics

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and develop a novel platform or chemical process for synthesizing antibiotic compounds with a $125,000 grant.

17 Sep 2024

DASH diet may lower the risk of cardiovascular disease in breast cancer survivors

A new paper in JNCI Cancer Spectrum, published by Oxford University Press, finds that following a healthy diet lowers the risk of cardiovascular disease in breast cancer survivors.

17 Apr 2024